In this Supplement
Valiant® Mona LSA Stent Graft Selected by the FDA for an early feasibility pilot program
How physicians, engineers, and regulatory agencies can work together to best serve patients with new technologies.
By Frank R. Arko, III, MD
Increasing AAA and TAA patient applicability while ensuring quality from design to market.
By Peter Larson, MS, BS; Emilie Simmons, MS; and Paige Bota, BS, PhD
The importance of clinical evidence in today’s medical practice.
By Kenneth Ouriel, MD, MBA
Endurant II Stent Graft Durable Outcomes in the ENGAGE Real-World Registry
By Pieter P.H.L. Broos, MD; Philippe W.M. Cuypers, MD, PhD; Joep A.W. Teijink, MD, PhD; and Marc R.H.M. van Sambeek, MD, PhD
Empowering EVAR clinical performance.
By Sharif H. Ellozy, MD
Hence J.M. Verhagen, MD, PhD, discusses how the Endurant II Stent Graft has performed well in challenging anatomy, enabling physicians to successfully treat a broader range of AAA patients.